|
Colorectal Neoplasms
|
0.420 |
GeneticVariation
|
group |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Neoplasms
|
0.420 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
Colorectal Neoplasms
|
0.420 |
Biomarker
|
group |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Neoplasms
|
0.420 |
GeneticVariation
|
group |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls.
|
31118516 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.
|
30054458 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes.
|
29358691 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
Our study establishes that a low-frequency allele in CCND2 halves the risk of type 2 diabetes primarily through enhanced insulin secretion.
|
25605810 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
Biomarker
|
disease |
CTD_human |
A low-frequency (1.47%) variant in intron 1 of CCND2, rs76895963[G], reduces risk of T2D by half (odds ratio (OR) = 0.53, P = 5.0 × 10(-21)) and is correlated with increased CCND2 expression.
|
24464100 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.420 |
AlteredExpression
|
disease |
BEFREE |
A low-frequency (1.47%) variant in intron 1 of CCND2, rs76895963[G], reduces risk of T2D by half (odds ratio (OR) = 0.53, P = 5.0 × 10(-21)) and is correlated with increased CCND2 expression.
|
24464100 |
2014 |
|
Colorectal Neoplasms
|
0.420 |
GeneticVariation
|
group |
GWASCAT |
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis.
|
23266556 |
2013 |
|
Colorectal Neoplasms
|
0.420 |
GeneticVariation
|
group |
BEFREE |
We also provided evidence for an association between colorectal tumor risk and polymorphisms in laminin gamma 1 (this is the second gene in the laminin family to be associated with colorectal cancers), cyclin D2 (which encodes for cyclin D2), and T-box 3 (which encodes a T-box transcription factor and is a target of Wnt signaling to β-catenin).
|
23266556 |
2013 |
|
Colorectal Neoplasms
|
0.420 |
AlteredExpression
|
group |
BEFREE |
Using a group based analysis it was possible to demonstrate, that tumors with an SUV >12 are associated with a high expression of cyclin D2 in the colorectal tumors.
|
21153447 |
2011 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutant U1-snRNA-mediated alternative splicing inactivates tumour suppressor genes (PTCH1), and activates oncogenes (GLI2, CCND2), represents a novel target for therapy, and constitutes a highly recurrent and tissue-specific mutation of a non-protein coding gene in cancer.
|
31597162 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results indicated CCND2/3 played an oncogenic role in all of the cancer patients (CCND2: pooled HR = 2.21, 95% CI: 1.67-2.93; CCND3: pooled HR = 2.29, 95% CI: 1.05-5.03).
|
30950241 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was a negative correlation between the expression of miR-615 and CCND2 in prostate cancer tissues.
|
29471894 |
2019 |
|
Hydrocephalus
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Novel CCND2 Mutation in a Previously Reported Case of Megalencephaly and Perisylvian Polymicrogyria with Postaxial Polydactyly and Hydrocephalus.
|
29642246 |
2018 |
|
Macrocephaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Novel CCND2 Mutation in a Previously Reported Case of Megalencephaly and Perisylvian Polymicrogyria with Postaxial Polydactyly and Hydrocephalus.
|
29642246 |
2018 |
|
Cerebral ventriculomegaly
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
A Novel CCND2 Mutation in a Previously Reported Case of Megalencephaly and Perisylvian Polymicrogyria with Postaxial Polydactyly and Hydrocephalus.
|
29642246 |
2018 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Using these tools, we characterize ongoing longitudinal characterization of a patient from the first trial to treat severe combined immunodeficiency-X1 (SCID-X1), showing successful reconstitution for 15 years accompanied by persistence of a cell clone with an integration site near the cancer-associated gene CCND2.
|
28344988 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, we have identified an association of genetic variants and genes in the RTK/ERK pathway with prostate cancer aggressiveness, and highlighted the potential importance of CCND2 in prostate cancer susceptibility and tumor progression to metastasis.
|
28674394 |
2017 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Post-treatment samples may also acquire mutations in known cancer driver genes (for example, SF3B1, TAF1 and CCND2) that are absent from the paired pre-treatment sample.
|
27045317 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 was highly tumour-specific in prostate cancer tissue.
|
27576364 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
|
25980436 |
2015 |